Applied Genetic Technologies Corp Price Target Increased to $34.00 by Analysts at BMO Capital Markets (AGTC)
Investment analysts at BMO Capital Markets boosted their price objective on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) from $21.00 to $34.00 in a note issued to investors on Monday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 58.73% from the stock’s previous close.
Shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) traded up 11.44% during mid-day trading on Monday, hitting $23.87. The stock had a trading volume of 83,199 shares. Applied Genetic Technologies Corp has a 52 week low of $11.10 and a 52 week high of $24.25. The stock’s 50-day moving average is $13.92 and its 200-day moving average is $14.15. The company’s market cap is $336.0 million.
Applied Genetic Technologies Corp (NASDAQ:AGTC) last announced its earnings results on Wednesday, May 14th. The company reported ($25.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $25.08. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.15 million. On average, analysts predict that Applied Genetic Technologies Corp will post $-14.11 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on AGTC. Analysts at Zacks initiated coverage on shares of Applied Genetic Technologies Corp in a research note on Wednesday, April 30th. They set a “hold” rating on the stock. Separately, analysts at Roth Capital initiated coverage on shares of Applied Genetic Technologies Corp in a research note on Monday, April 21st. They set a “buy” rating on the stock. Finally, analysts at Wedbush initiated coverage on shares of Applied Genetic Technologies Corp in a research note on Monday, April 21st. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $27.50.
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.